CELL GENESYS REPORTS ON TRIAL OF CG0070 -- UPDATE
Cell Genesys has announced preliminary results of a Phase I clinical trial of CG0070 in patients with recurrent bladder cancer who have failed previous therapy with bacillus Calmette-Guerin, the current standard therapy for recurrent bladder cancer.
Nine patients have been treated with escalating single-dose administrations of CG0070. Evidence of antitumor activity documented by a complete response at follow-up cystoscopy was obtained in three of the nine patients treated. Treatment was tolerable with no serious adverse events or dose limiting toxicities reported to date.